Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors

Gelijkaardige items

• BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships
  door: Khorashad, Jamshid S., et al.
  Gepubliceerd in: (2013)
• Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
  door: Qiang, Wang, et al.
  Gepubliceerd in: (2017)
• Kinase Inhibitor Therapy in CML: It's What's Inside That Counts
  door: Eide, Christopher A., et al.
  Gepubliceerd in: (2013)
• Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
  door: Zabriskie, Matthew S., et al.
  Gepubliceerd in: (2015)
• Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
  door: Carofiglio, Francesca, et al.
  Gepubliceerd in: (2020)